- Home
- III vs NTHI Comparison
III vs NTHI Comparison
Compare III & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- NTHI
- Stock Information
- Founded
- III 2006
- NTHI 2008
- Country
- III United States
- NTHI United States
- Employees
- III N/A
- NTHI N/A
- Industry
- III Professional Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- III Consumer Discretionary
- NTHI Health Care
- Exchange
- III Nasdaq
- NTHI Nasdaq
- Market Cap
- III 249.2M
- NTHI 211.9M
- IPO Year
- III 2007
- NTHI N/A
- Fundamental
- Price
- III $5.42
- NTHI $10.35
- Analyst Decision
- III Buy
- NTHI
- Analyst Count
- III 1
- NTHI 0
- Target Price
- III $5.50
- NTHI N/A
- AVG Volume (30 Days)
- III 247.9K
- NTHI 58.8K
- Earning Date
- III 11-03-2025
- NTHI 11-19-2025
- Dividend Yield
- III 3.32%
- NTHI N/A
- EPS Growth
- III N/A
- NTHI N/A
- EPS
- III 0.16
- NTHI N/A
- Revenue
- III $240,201,000.00
- NTHI $59,990.00
- Revenue This Year
- III N/A
- NTHI N/A
- Revenue Next Year
- III $4.84
- NTHI N/A
- P/E Ratio
- III $34.54
- NTHI N/A
- Revenue Growth
- III N/A
- NTHI N/A
- 52 Week Low
- III $2.95
- NTHI $3.20
- 52 Week High
- III $6.01
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- III 48.44
- NTHI N/A
- Support Level
- III $5.18
- NTHI N/A
- Resistance Level
- III $5.61
- NTHI N/A
- Average True Range (ATR)
- III 0.22
- NTHI 0.00
- MACD
- III -0.05
- NTHI 0.00
- Stochastic Oscillator
- III 29.07
- NTHI 0.00
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).